Researchers confirm the need for cardiac follow-up in patients with Friedreich ataxia, with particular focus on left ventricular ejection fraction (LVEF) as a predictor of worse prognosis. They ...

Friedreich’s ataxia is an ultra-rare, inherited neurodegenerative disorder that is typically diagnosed during adolescence. Patients with Friedreich’s ataxia experience progressive loss of coordination ...

TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with ...

Please provide your email address to receive an email when new articles are posted on . Approximately 5,000 people in the United States have Friedreich’s ataxia. Advocates virtually met with ...

Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress. The Food and Drug Administration (FDA) has approved Skyclarys ™ (omaveloxolone) for the treatment ...

Please provide your email address to receive an email when new articles are posted on . Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years ...

Friedreich ataxia (FA) is a rare, hereditary neurodegenerative disease that causes difficulties with coordination and balance and reduces lifespan. The disease affects approximately 1 in 50,000 people ...

IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE ...

Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its ...

AJMC ®: What is your experience in treating patients with Friedreich ataxia (FA)? PERLMAN: I’m an adult neurologist with over 30 years of experience in an academic medical setting, primarily focusing ...

Friedreich’s ataxia is a neuromuscular condition that causes progressive loss of mobility and independence. In most cases, symptoms begin early in life, and many people with the condition begin ...

PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical ...